REAL-WORLD WEIGHT OUTCOMES FOLLOWING INITIATION OF GLP-1 RECEPTOR AGONIST ANTI-OBESITY MEDICATIONS IN A MISSISSIPPI MEDICAID POPULATION
Author(s)
Liang-Yuan Lin, MS1, Junnan Qi, MS1, Lindy Harper, BS2, Dennis Smith, BSPharm, RPh3, Amy Ly-Ha, PharmD3, Terri Kirby, BSPharm, RPh3, Tricia Banks, PharmD4, Eric Pittman, PharmD, PhD1, Kaustuv Bhattacharya, PhD1;
1Department of Pharmacy Administration, University of Mississippi, University, MS, USA, 2University of Mississippi, Pharmacy, Oxford, MS, USA, 3Mississippi Division of Medicaid, Jackson, MS, USA, 4Gainwell Technologies, Jackson, MS, USA
1Department of Pharmacy Administration, University of Mississippi, University, MS, USA, 2University of Mississippi, Pharmacy, Oxford, MS, USA, 3Mississippi Division of Medicaid, Jackson, MS, USA, 4Gainwell Technologies, Jackson, MS, USA
OBJECTIVES: To evaluate real-world weight and body mass index (BMI) changes among Mississippi Medicaid members initiating glucagon-like peptide-1 receptor agonist anti-obesity medications (GLP-1 RA AOMs), and to assess the impact of adherence, persistence, and treatment switching on weight outcomes.
METHODS: This study used Mississippi Medicaid claims data linked with prior authorization (PA) records from July 2023 through June 2024. Adult GLP-1 RA AOM initiators with at least two PA assessments and continuous enrollment were included. The PA assessment closest to the first medication fill served as baseline, and closest to the 6th (4 - 8 month) and 12th (10 - 14 month) months served as the follow-up assessments. Outcomes included changes in weight, BMI, and the proportion achieving ≥5% weight loss. Adherence was measured using proportion of days covered, and persistence was defined as continuous treatment without a ≥60-day gap. Descriptive statistics were used to summarize weight outcomes. Chi-square tests were conducted to examine associations between weight change categories (weight gain versus weight loss) and baseline characteristics and medication use patterns.
RESULTS: The study included 393 members in the 6-month cohort and 267 in the 12-month cohort. Mean baseline weight was 268 lbs and mean BMI was 44.4 kg/m².[AL1] At 6 months, members lost an average of 15.3 lbs, and 21.7 lbs at 12 months. Overall, 57.0% and 64.4% of the members achieved ≥5% weight loss at 6 months and 12 months respectively. High adherence and persistence were associated with weight loss, whereas switching was associated with weight gain. Demographic and clinical characteristics were not significantly associated with weight outcomes.
CONCLUSIONS: Among Mississippi Medicaid GLP-1 RA AOM initiators, clinically meaningful weight loss was observed, particularly among those with high adherence and persistence. Medication adherence and persistence patterns were the primary drivers of weight outcomes, underscoring the importance of sustained therapy in real-world obesity management.
METHODS: This study used Mississippi Medicaid claims data linked with prior authorization (PA) records from July 2023 through June 2024. Adult GLP-1 RA AOM initiators with at least two PA assessments and continuous enrollment were included. The PA assessment closest to the first medication fill served as baseline, and closest to the 6th (4 - 8 month) and 12th (10 - 14 month) months served as the follow-up assessments. Outcomes included changes in weight, BMI, and the proportion achieving ≥5% weight loss. Adherence was measured using proportion of days covered, and persistence was defined as continuous treatment without a ≥60-day gap. Descriptive statistics were used to summarize weight outcomes. Chi-square tests were conducted to examine associations between weight change categories (weight gain versus weight loss) and baseline characteristics and medication use patterns.
RESULTS: The study included 393 members in the 6-month cohort and 267 in the 12-month cohort. Mean baseline weight was 268 lbs and mean BMI was 44.4 kg/m².[AL1] At 6 months, members lost an average of 15.3 lbs, and 21.7 lbs at 12 months. Overall, 57.0% and 64.4% of the members achieved ≥5% weight loss at 6 months and 12 months respectively. High adherence and persistence were associated with weight loss, whereas switching was associated with weight gain. Demographic and clinical characteristics were not significantly associated with weight outcomes.
CONCLUSIONS: Among Mississippi Medicaid GLP-1 RA AOM initiators, clinically meaningful weight loss was observed, particularly among those with high adherence and persistence. Medication adherence and persistence patterns were the primary drivers of weight outcomes, underscoring the importance of sustained therapy in real-world obesity management.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO12
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity)